

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L2	3	l1 and PIPERAZINYLACYLPIDERIDINE.ti.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/07/27 18:30

=> b reg
 FILE 'REGISTRY' ENTERED AT 15:33:11 ON 27 JUL 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 26 JUL 2007 HIGHEST RN 943513-14-2
 DICTIONARY FILE UPDATES: 26 JUL 2007 HIGHEST RN 943513-14-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=> d que sta 19
 L7 STR



REP G1=(1-2) C
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 GGCAT IS UNS AT 22
 DEFAULT ECLEVEL IS LIMITED
 ECOUNT IS E4 C E2 N AT 22


GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 22

STEREO ATTRIBUTES: NONE
 L9 127 SEA FILE=REGISTRY SSS FUL L7

100.0% PROCESSED 8832 ITERATIONS
 SEARCH TIME: 00.00.01

127 ANSWERS

=> d que sta 111
 L7 STR



REP G1=(1-2) C
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 GGCAT IS UNS AT 22
 DEFAULT ECLEVEL IS LIMITED
 ECOUNT IS E4 C E2 N AT 22

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 22

STEREO ATTRIBUTES: NONE
 L9 127 SEA FILE=REGISTRY SSS FUL L7
 L10 73363 SEA FILE=REGISTRY ABB=ON PLU=ON 46.383.21/RID
 L11 98 SEA FILE=REGISTRY ABB=ON PLU=ON L9 AND L10

=> b hcap
 FILE 'HCAPLUS' ENTERED AT 15:33:24 ON 27 JUL 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Jul 2007 VOL 147 ISS 6
 FILE LAST UPDATED: 26 Jul 2007 (20070726/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs hitrn fhitr l14 tot

L14 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN
 AN 2005:470969 HCAPLUS
 DN 143:26636
 TI Preparation of 4-[(Arylmethyl)aminomethyl]piperidines as inhibitors of NGF binding (nerve growth factor) to p75NTR (p75 neurotrophic) receptor for treating p75NTR related diseases
 IN Bosch, Michael; Wagnon, Jean
 PA Sanofi-Synthelabo, Fr.
 SO Fr. Demande, 31 pp.
 CODEN: FRXXBL
 DT Patent
 LA French
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR---2862968	A1	20050603	2003FR-0014172	20031201

```

FR---2862968      B1      20060804
WO2005054229      A1      20050616      2004WO-FR03066      20041130
W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
    CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
    GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
    LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
    NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
    TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW:  BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
    AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
    EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,
    SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
    NE, SN, TD, TG
EP---1694668      A1      20060830      2004EP-0805590      20041130
R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
    IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
    HR, IS, YU
JP2007512384      T      20070517      2006JP-0541974      20041130
US2007037819      A1      20070215      2006US-0420505      20060526
PRAI 2003FR-0014172      A      20031201
      2004WO-FR03066      W      20041130
OS  MARPAT 143:26636
GI

```

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein X = (CH₂)_n; n = 1-2; R₁ = CF₃; R₂ = H, alkyl; R₃ = (un)substituted pyrrolyl, 1,2,3-thiadiazolyl, pyrazinyl, etc.; and their salts, hydrates and solvates] were prepared as inhibitors of the binding of 125I NGF to p75NTR (p75 neurotrophic) receptor and of the apoptosis induced by NGF (nerve growth factor) for treating p75NTR related diseases (no data). For example, II was prepared by reacting 1-[4-(aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone (preparation given) and 1-methyl-2-pyrrolicarboxaldehyde in THF in the presence of NaBH(OAc)₃/AcOH. I inhibited the binding of 125I NGF to p75NTR receptor with IC₅₀ in the range of 10⁻¹¹ M to 10⁻⁶ M at the biochem. level. I inhibited the pro-apoptotic effect induced by NGF, via growing cells expressing preferentially p75NTR, with IC₅₀ in the range of 10⁻¹¹ M to 10⁻⁶ M at the cellular level.

IT 852936-29-9P, [(1-Methyl-1H-pyrrol-2-yl)methyl] [[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl]amine 852936-31-3P 852936-32-4P, N-Methyl-1-[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]-N-[(1,3-thiazol-2-yl)methyl]methanamine trihydrochloride 852936-33-5P, (2-Furylmethyl) [[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl]amine 852936-34-6P, (3-Furylmethyl) [[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl]amine 852936-35-7P, [(5-Methyl-2-furyl)methyl] [[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl]amine 852936-36-8P, [(4,5-Dimethyl-2-furyl)methyl] (methyl) [[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl]amine trihydrochloride 852936-37-9P, [(5-Chloro-2-furyl)methyl] (methyl) [[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl]amine 852936-38-0P, [[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl] [(2-thienyl)methyl]amine 852936-39-1P, [[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl] [(3-thienyl)methyl]amine 852936-40-4P, 1-Phenyl-N-[[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl]methanamine 852936-41-5P, [[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl] [(pyridin-2-yl)methyl]amine 852936-42-6P, N-Methyl-1-[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]-N-[(pyridin-2-yl)methyl]methanamine 852936-43-7P, N-Methyl-1-[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]-N-[(pyridin-3-yl)methyl]methanamine tetrahydrochloride 852936-44-8P, N-Methyl-1-[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]-N-[(pyridin-4-yl)methyl]methanamine tetrahydrochloride 852936-45-9P, N-Methyl-1-(pyrazin-2-yl)-N-[[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-

[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]methanamine tetrahydrochloride 852936-46-0P, [(6-Methylpyridin-2-yl)methyl][[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]amine 852936-47-1P, [(3-Methyl-2-thienyl)methyl][[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]amine trihydrochloride 852936-48-2P 852936-49-3P, N-Methyl-1-[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]-N-[(pyrimidin-5-yl)methyl]methanamine 852936-50-6P, (1H-Imidazol-2-ylmethyl)(methyl)[[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]amine 852936-51-7P, (1H-Imidazol-5-ylmethyl)(methyl)[[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]amine tetrahydrochloride 852936-52-8P, N-Methyl-1-(4-methyl-1H-imidazol-5-yl)-N-[[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]pyridin-4-yl)methyl]methanamine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 4-[(arylmethyl)aminomethyl]piperidines as NGF binding inhibitors to p75NTR receptor and of the apoptosis induced by NGF)

IT 634461-23-7P, 1-[4-(Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
 634464-08-7P, 1-[4-[(Methylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634469-57-1P, tert-Butyl [[1-[2-[4-(2-pyrazinyl)-1-piperazinyl]ethanoyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinyl]methyl]carbamate 852936-54-0P, tert-Butyl [[1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinyl]methyl]carbamate
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(intermediate; preparation of 4-[(arylmethyl)aminomethyl]piperidines as NGF binding inhibitors to p75NTR receptor and of the apoptosis induced by NGF)

IT 852936-29-9P, [(1-Methyl-1H-pyrrol-2-yl)methyl][[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]amine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 4-[(arylmethyl)aminomethyl]piperidines as NGF binding inhibitors to p75NTR receptor and of the apoptosis induced by NGF)

RN 852936-29-9 HCAPLUS

CN 4-Piperidinemethanamine, N-[(1-methyl-1H-pyrrol-2-yl)methyl]-1-[(4-pyrazinyl-1-piperazinyl)acetyl]-4-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:991506 HCAPLUS

DN 140:27846

TI Preparation of piperazinylacylpiperidines as inhibitors of NGF binding (nerve growth factor) to p75NTR (p75 neurotrophic) receptor for treating p75NTR related diseases

IN Bono, Francoise; Bosch, Michael; Dos, Santos Victor; Herbert, Jean Marc; Nisato, Dino; Tonnerre, Bernard; Wagnon, Jean



PA Sanofi-Synthelabo, Fr.; Dos Santos, Victor

SO PCT Int. Appl., 81 pp.

CODEN: PIXXD2

DT Patent
LA French
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2003104225	A1	20031218	2003WO-FR01685	20030605
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA---2487840	A1	20031218	2003CA-2487840	20030605
	AU2003255644	A1	20031222	2003AU-0255644	20030605
	EP---1513835	A1	20050316	2003EP-0757108	20030605
	EP---1513835	B1	20060816		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR2003011828	A	20050329	2003BR-0011828	20030605
	US2005176722	A1	20050811	2003US-0516704	20030605
	CN---1675203	A	20050928	2003CN-0818808	20030605
	JP2005534661	T	20051117	2004JP-0511295	20030605
	AT---325122	T	20060615	2003AT-0757109	20030605
	NZ---537044	A	20060831	2003NZ-0537044	20030605
	AT---336491	T	20060915	2003AT-0757108	20030605
	PT---1513836	T	20060929	2003PT-0757109	20030605
	ES---2264001	T3	20061216	2003ES-3757109	20030605
	ZA2004009823	A	20060726	2004ZA-0009823	20041203
	NO2004005331	A	20050307	2004NO-0005331	20041206
	IN2004KN01862	A	20060407	2004IN-KN01862	20041206
	MX2004PA12341	A	20050930	2004MX-PA12341	20041207
PRAI	2002FR-0007001	A	20020607		
	2003WO-FR01685	W	20030605		
OS	MARPAT 140:27846				
GI					



AB Title compds. I [wherein: Y = (CH₂)_n; n = 1 or 2; X = (CH₂)_p; p = 1 or 2; R₁ = halo, CF₃, alkyl, alkoxy, trifluoromethoxy; R₂ = H, halo; R₃ = H, OR₅, CH₂OR₅, NH₂ and derivs., NHCOR₆ and derivs., NHCONH₂ and derivs., CH₂NR₇R₈, CH₂NHCONH₂ and derivs., alkoxycarbonyl, CONH₂ and derivs.; or R₃ forms a double bond between the carbon atom where it is bound to and the neighboring carbon atom of the piperidine cycle; R₄ = (un)substituted pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, 3(2H)-pyridazinon-5-yl, 3(2H)-pyridazinon-4-yl; R₅ = H, alkyl, alkylcarbonyl; R₆ = alkyl, (CH₂)_mNH₂ and derivs.; m = 1, 2, or 3; R₇, R₈ = independently H, alkyl; R₈ = (CH₂)_qOH, (CH₂)_qSM_e; q = 2 or 3; or R₇R₈N = aziridine, azetidine,

pyrrolidine, piperidine, morpholine; and their salts, hydrates and solvates) were prepared as inhibitors of the binding of 125I NGF to p75NTR (p75 neurotrophic) receptor and of the apoptosis induced by NGF (nerve growth factor) for treating p75NTR related diseases (no data). For example, II•HCl was prepared by reacting 1-(2-pyrazinyl)piperazine (preparation given) with 2-chloro-1-[4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-1-ethanone (preparation given) in the presence of KI/K₂CO₃/MeCN, followed by acidulation with HCl. I inhibited the binding of 125I NGF to p75NTR receptor with IC₅₀ in the range of 10⁻¹¹ M to 10⁻⁶ M at the biochem. level. I inhibited the pro-apoptotic effect induced by NGF, via growing cells expressing preferentially p75NTR, with IC₅₀ in the range of 10⁻¹¹ M to 10⁻⁶ M at the cellular level.

IT 634461-23-7P, 1-[4-(Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
634461-69-1P 634462-72-9P 634462-91-2P
634463-08-4P 634463-19-7P 634463-39-1P
634464-66-7P 634525-03-4P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(NGF binding inhibitor; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)

IT 634461-08-8P, 2-[4-(2-Pyrazinyl)-1-piperazinyl]-1-[4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-1-ethanone monohydrochloride
634461-18-0P, 1-[4-Hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-3-[4-(2-(pyrazinyl))-1-piperazinyl]-1-propanone oxalate
634462-26-3P 634462-32-1P 634462-38-7P
634462-55-8P 634462-61-6P 634462-68-3P
634462-79-6P, 1-[4-(Hydroxymethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
634462-83-2P, 1-[4-[(Dimethylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634462-87-6P 634462-98-9P,
1-[4-(4-Chlorophenyl)-3,6-dihydro-1(2H)-pyridinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634463-03-9P, 1-[4-(Aminomethyl)-4-(4-chlorophenyl)-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Trifluoroacetate 634463-13-1P 634463-23-3P
634463-44-8P 634463-77-7P 634463-93-7P
634464-08-7P, 1-[4-[(Methylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634464-15-6P, 1-[4-[(Isopropylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634464-20-3P, 1-[4-[(N-Methylisopropylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Trihydrochloride 634464-24-7P
634464-29-2P 634464-34-9P 634464-39-4P
634464-44-1P 634464-48-5P, 1-[4-(Aminomethyl)-4-(3-chlorophenyl)-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634464-72-5P, 1-[4-(Aminomethyl)-4-(3-methoxyphenyl)-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Dioxalate 634470-24-9P 634525-08-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(NGF binding inhibitor; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)

IT 634464-71-4P 634469-50-4P, 1-[2-[4-(2-Pyrazinyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinecarbonitrile
634469-57-1P, tert-Butyl [[1-[2-[4-(2-pyrazinyl)-1-piperazinyl]-1-oxoethyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinyl]methyl]carbamate
634469-68-4P 634469-69-5P 634469-74-2P,
4-(4-Chlorophenyl)-1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinecarbonitrile 634469-86-6P, tert-Butylmethyl [[1-[2-[4-(2-pyrazinyl)-1-piperazinyl]1-oxoethyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinyl]methyl]carbamate
634469-90-2P, 4-(3-Chlorophenyl)-1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinecarbonitrile 634469-97-9P,
4-(3-Methoxyphenyl)-1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinecarbonitrile

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)


IT 634469-80-0P, 1-[4-(Aminomethyl)-4-phenyl-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (intermediate; preparation of piperazinylaclylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)

IT 634469-81-1P, 1-[4-(Aminomethyl)-4-phenyl-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Trifluoroacetate
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of piperazinylaclylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)

IT 634461-23-7P, 1-[4-(Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (NGF binding inhibitor; preparation of piperazinylaclylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)

RN 634461-23-7 HCAPLUS

CN 4-Piperidinemetanamine, 1-[(4-pyrazinyl-1-piperazinyl)acetyl]-4-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)





RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib abs hitstr 117 tot

L17 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN
 AN 2003:991506 HCAPLUS
 DN 140:27846
 TI Preparation of piperazinylaclylpiperidines as inhibitors of NGF binding
 (nerve growth factor) to p75NTR (p75 neurotrophic) receptor for treating
 p75NTR related diseases
 IN Bono, Francoise; Bosch, Michael; Dos, Santos Victor; Herbert, Jean Marc;
 Nisato, Dino; Tonnerre, Bernard; Wagnon, Jean
 PA Sanofi-Synthelabo, Fr.; Dos Santos, Victor
 SO PCT Int. Appl., 81 pp.
 CODEN: PIXXD2
 DT Patent
 LA French
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO2003104225	A1	20031218	2003WO-FR01685	20030605
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA---2487840	A1	20031218	2003CA-2487840	20030605
AU2003255644	A1	20031222	2003AU-0255644	20030605
EP---1513835	A1	20050316	2003EP-0757108	20030605
EP---1513835	B1	20060816		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR2003011828	A	20050329	2003BR-0011828	20030605

US2005176722	A1	20050811	2003US-0516704	20030605
CN---1675203	A	20050928	2003CN-0818808	20030605
JP2005534661	T	20051117	2004JP-0511295	20030605
AT----325122	T	20060615	2003AT-0757109	20030605
NZ---537044	A	20060831	2003NZ-0537044	20030605
AT---336491	T	20060915	2003AT-0757108	20030605
PT---1513836	T	20060929	2003PT-0757109	20030605
ES---2264001	T3	20061216	2003ES-3757109	20030605
ZA2004009823	A	20060726	2004ZA-0009823	20041203
NO2004005331	A	20050307	2004NO-0005331	20041206
IN2004KN01862	A	20060407	2004IN-KN01862	20041206
MX2004PA12341	A	20050930	2004MX-PA12341	20041207
PRAI 2002FR-0007001	A	20020607		
2003WO-FR01685	W	20030605		
OS MARPAT 140:27846				
GI				




AB Title compds. I [wherein: Y = (CH₂)_n; n = 1 or 2; X = (CH₂)_p; p = 1 or 2; R₁ = halo, CF₃, alkyl, alkoxy, trifluoromethoxy; R₂ = H, halo; R₃ = H, OR₅, CH₂OR₅, NH₂ and derivs., NHCOR₆ and derivs., NHCONH₂ and derivs., CH₂NR₇R₈, CH₂NHCONH₂ and derivs., alkoxycarbonyl, CONH₂ and derivs.; or R₃ forms a double bond between the carbon atom where it is bound to and the neighboring carbon atom of the piperidine cycle; R₄ = (un)substituted pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, 3(2H)-pyridazinon-5-yl, 3(2H)-pyridazinon-4-yl; R₅ = H, alkyl, alkylcarbonyl; R₆ = alkyl, (CH₂)_mNH₂ and derivs.; m = 1, 2, or 3; R₇, R₈ = independently H, alkyl; R₈ = (CH₂)_qOH, (CH₂)_qSM_e; q = 2 or 3; or R₇R₈N = aziridine, azetidine, pyrrolidine, piperidine, morpholine; and their salts, hydrates and solvates] were prepared as inhibitors of the binding of ¹²⁵I NGF to p75NTR (p75 neurotrophic) receptor and of the apoptosis induced by NGF (nerve growth factor) for treating p75NTR related diseases (no data). For example, II•HCl was prepared by reacting 1-(2-pyrazinyl)piperazine (preparation given) with 2-chloro-1-[4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-1-ethanone (preparation given) in the presence of KI/K₂CO₃/MeCN, followed by acidulation with HCl. I inhibited the binding of ¹²⁵I NGF to p75NTR receptor with IC₅₀ in the range of 10⁻¹¹ M to 10⁻⁶ M at the biochem. level. I inhibited the pro-apoptotic effect induced by NGF, via growing cells expressing preferentially p75NTR, with IC₅₀ in the range of 10⁻¹¹ M to 10⁻⁶ M at the cellular level.


IT 634462-55-8P 634462-61-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (NGF binding inhibitor; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)

RN 634462-55-8 HCAPLUS
 CN Pyridine, 1,2,3,6-tetrahydro-1-[(4-pyrazinyl-1-piperazinyl)acetyl]-4-[3-(trifluoromethyl)phenyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)


CM 1.

CRN 634462-54-7
CMF C22 H24 F3 N5 O


CM 2

CRN 144-62-7
CMF C2 H2 O4RN 634462-61-6 HCAPLUS
CN Pyridine, 1,2,3,6-tetrahydro-1-[(4-pyrazinyl-1-piperazinyl)acetyl]-4-[2-(trifluoromethyl)phenyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 634462-60-5
CMF C22 H24 F3 N5 O

CM 2

CRN 144-62-7
CMF C2 H2 O4RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> b uspatall

FILE 'USPATFULL' ENTERED AT 15:33:59 ON 27 JUL 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)FILE 'USPAT2' ENTERED AT 15:33:59 ON 27 JUL 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitrn fhitr 119 tot

L19 ANSWER 1 OF 3 USPATFULL on STN

AN 2007:43120 USPATFULL

TI 4-[(ARYLMETHYL)AMINOMETHYL]PIPERIDINE DERIVATIVES, THEIR PREPARATION AND
THEIR THERAPEUTIC APPLICATION

IN Bosch, Michael, Marsillargues, FRANCE

Wagnon, Jean, Montpellier, FRANCE
 PA sanofi-aventis, Paris, FRANCE (non-U.S. corporation)
 PI US-20070037819 A1 20070215
 AI 2006US-000420505 A1 20060526 (11)
 RLI Continuation of Ser. No. 2004WO-FR0003066, filed on 30 Nov 2004, UNKNOWN
 PRAI 2003FR-0000014172 20031201
 DT Utility
 FS APPLICATION
 LREP ROSS J. OEHLER, SANOFI-AVENTIS U.S. LLC, 1041 ROUTE 202-206, MAIL CODE:
 D303A, BRIDGEWATER, NJ, 08807, US
 CLMN Number of Claims: 14
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 948

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to 4-[(arylmethyl)aminomethyl]piperidine derivatives of general formula (I) ##STR1## in the form of a base or an addition salt with an acid, and also in the form of a hydrate or solvate, and their preparation process and therapeutic application.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 852936-29-9P, [(1-Methyl-1H-pyrrol-2-yl)methyl][(1-[(4-(pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]amine 852936-31-3P 852936-32-4P, N-Methyl-1-[1-[(4-(pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]-N-[(1,3-thiazol-2-yl)methyl]methanamine trihydrochloride 852936-33-5P, (2-Furylmethyl)[(1-[(4-(pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]amine 852936-34-6P, (3-Furylmethyl)[(1-[(4-(pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]amine 852936-35-7P, [(5-Methyl-2-furyl)methyl][(1-[(4-(pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]amine 852936-36-8P, [(4,5-Dimethyl-2-furyl)methyl](methyl)[(1-[(4-(pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]amine trihydrochloride 852936-37-9P, [(5-Chloro-2-furyl)methyl](methyl)[(1-[(4-(pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]amine 852936-38-0P, [(1-[(4-(pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl][(2-thienyl)methyl]amine 852936-39-1P, [(1-[(4-(pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl][(3-thienyl)methyl]amine 852936-40-4P, 1-Phenyl-N-[(1-[(4-(pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]methanamine 852936-41-5P, [(1-[(4-(pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl][(pyridin-2-yl)methyl]amine 852936-42-6P, N-Methyl-1-[1-[(4-(pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]-N-[(pyridin-2-yl)methyl]methanamine 852936-43-7P, N-Methyl-1-[1-[(4-(pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]-N-[(pyridin-3-yl)methyl]methanamine tetrahydrochloride 852936-44-8P, N-Methyl-1-[1-[(4-(pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]-N-[(pyridin-4-yl)methyl]methanamine tetrahydrochloride 852936-45-9P, N-Methyl-1-(pyrazin-2-yl)-N-[(1-[(4-(pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]methanamine tetrahydrochloride 852936-46-0P, [(6-Methylpyridin-2-yl)methyl][(1-[(4-(pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]amine 852936-47-1P, [(3-Methyl-2-thienyl)methyl][(1-[(4-(pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]amine trihydrochloride 852936-48-2P 852936-49-3P, N-Methyl-1-[1-[(4-(pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]-N-[(pyrimidin-5-yl)methyl]methanamine 852936-50-6P, (1H-Imidazol-2-ylmethyl)(methyl)[(1-[(4-(pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]amine 852936-51-7P, (1H-Imidazol-5-ylmethyl)(methyl)[(1-[(4-(pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]amine tetrahydrochloride 852936-52-8P, N-Methyl-1-(4-methyl-1H-imidazol-5-yl)-N-[(1-[(4-(pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]pyridin-4-yl)methyl]methanamine (drug candidate; preparation of 4-[(arylmethyl)aminomethyl]piperidines as NGF binding inhibitors to p75NTR receptor and of the apoptosis induced by NGF)


IT 634461-23-7P, 1-[4-(Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-

piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
 634464-08-7P, 1-[4-[(Methylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634469-57-1P, tert-Butyl [[1-[2-[4-(2-pyrazinyl)-1-piperazinyl]ethanoyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinyl]methyl]carbamate 852936-54-0P, tert-Butyl [[1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinyl]methyl]carbamate (intermediate; preparation of 4-[(arylmethyl)aminomethyl]piperidines as NGF binding inhibitors to p75NTR receptor and of the apoptosis induced by NGF)

IT 852936-29-9P, [(1-Methyl-1H-pyrrol-2-yl)methyl] [[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl]amine (drug candidate; preparation of 4-[(arylmethyl)aminomethyl]piperidines as NGF binding inhibitors to p75NTR receptor and of the apoptosis induced by NGF)

RN 852936-29-9 USPATFULL

CN 4-Piperidinemethanamine, N-[(1-methyl-1H-pyrrol-2-yl)methyl]-1-[(4-pyrazinyl-1-piperazinyl)acetyl]-4-[3-(trifluoromethyl)phenyl]- (9CI)
 (CA INDEX NAME)



L19 ANSWER 2 OF 3 USPATFULL on STN

AN 2006:196251 USPATFULL

TI Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof

IN Bono, Francoise, Toulouse, FRANCE
 Bosch, Michael, Marsillargues, FRANCE
 Dos Santos, Victor, Valergues, FRANCE
 Herbert, Jean-Marc, Tournefeuille, FRANCE
 Nisato, Dino, Saint-Georges D'Orques, FRANCE
 Tonnerre, Bernard, Vailhauques, FRANCE
 Wagnon, Jean, Montpellier, FRANCE

PA sanofi-aventis, 75013 Paris, FRANCE (non-U.S. corporation)

PI US-20060167007 A1 20060727

AI 2003US-000516808 A1 20030605 (10)

2003WO-FR0001686 20030605

20041203 PCT 371 date

PRAI 2002FR-0000007001 20020607

DT Utility

FS APPLICATION

LREP ROSS J. OEHLER, AVENTIS PHARMACEUTICALS INC., 1041 ROUTE 202-206, MAIL CODE: D303A, BRIDGEWATER, NJ, 08807, US

CLMN Number of Claims: 14

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2025

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to substituted 1-piperazinylacylpiperidine derivatives of general formula (I) ##STR1## in which: n is 1 or 2;

R.sub.1 represents a halogen atom; a trifluoromethyl radical; a (C.sub.1-C.sub.4) alkyl; a (C.sub.1-C.sub.4)alkoxy; a trifluoromethoxy radical;

R.sub.2 represents a hydrogen atom or a halogen atom;

R.sub.3 represents a hydrogen atom; a group --OR.sub.5; a group --CH.sub.2OR.sub.5; a group --NR.sub.6R.sub.7; a group --NR.sub.8COR.sub.9; a group --NR.sub.8CONR.sub.10R.sub.11; a group --CH.sub.2NR.sub.12R.sub.13; a group --CH.sub.2NR.sub.8CONR.sub.14R.sub.15; a (C.sub.1-C.sub.4)alkoxycarbonyl; a group --CONR.sub.16R.sub.17;

or else R.sub.3 constitutes a double bond between the carbon atom to which it is attached and the adjacent carbon atom of the piperidine ring;

R.sub.4 represents the aromatic group 1,3-thiazol-2-yl of formula:
##STR2## Preparation process and therapeutic application.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

- IT 634461-23-7P, 1-[4-(Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
634461-69-1P 634462-72-9P 634462-91-2P
634463-08-4P 634463-19-7P 634463-39-1P
634464-66-7P 634525-03-4P
(NGF binding inhibitor; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
- IT 634461-08-8P, 2-[4-(2-Pyrazinyl)-1-piperazinyl]-1-[4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-1-ethanone monohydrochloride
634461-18-0P, 1-[4-Hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-3-[4-(2-(pyrazinyl))-1-piperazinyl]-1-propanone oxalate
634462-26-3P 634462-32-1P 634462-38-7P
634462-55-8P 634462-61-6P 634462-68-3P
634462-79-6P, 1-[4-(Hydroxymethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
634462-83-2P, 1-[4-[(Dimethylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634462-87-6P 634462-98-9P,
1-[4-(4-Chlorophenyl)-3,6-dihydro-1(2H)-pyridinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634463-03-9P, 1-[4-(Aminomethyl)-4-(4-chlorophenyl)-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
Trifluoroacetate 634463-13-1P 634463-23-3P
634463-44-8P 634463-77-7P 634463-93-7P
634464-08-7P, 1-[4-[(Methylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634464-15-6P, 1-[4-[(Isopropylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634464-20-3P, 1-[4-[(N-Methylisopropylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Trihydrochloride 634464-24-7P
634464-29-2P 634464-34-9P 634464-39-4P
634464-44-1P 634464-48-5P, 1-[4-(Aminomethyl)-4-(3-chlorophenyl)-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
634464-72-5P, 1-[4-(Aminomethyl)-4-(3-methoxyphenyl)-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Dioxalate
634470-24-9P 634525-08-9P
(NGF binding inhibitor; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
- IT 634464-71-4P 634469-50-4P, 1-[2-[4-(2-Pyrazinyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinecarbonitrile 634469-57-1P, tert-Butyl [[1-[2-[4-(2-pyrazinyl)-1-piperazinyl]-1-oxoethyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinyl]methyl]carbamate
634469-68-4P 634469-69-5P 634469-74-2P,
4-(4-Chlorophenyl)-1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinecarbonitrile 634469-86-6P, tert-Butylmethyl [[1-[2-[4-(2-pyrazinyl)-1-piperazinyl]-1-oxoethyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinyl]methyl]carbamate
634469-90-2P, 4-(3-Chlorophenyl)-1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinecarbonitrile 634469-97-9P,
4-(3-Methoxyphenyl)-1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinecarbonitrile
(intermediate; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
- IT 634469-80-0P, 1-[4-(Aminomethyl)-4-phenyl-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
(intermediate; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
- IT 634469-81-1P, 1-[4-(Aminomethyl)-4-phenyl-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Trifluoroacetate
(preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
- IT 634461-23-7P, 1-[4-(Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone

(NGF binding inhibitor; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)

RN 634461-23-7 USPATFULL

CN 4-Piperidinemethanamine, 1-[(4-pyrazinyl-1-piperazinyl)acetyl]-4-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L19 ANSWER 3 OF 3 USPATFULL on STN

AN 2005:203297 USPATFULL

TI Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof

IN Bono, Francoise, Toulouse, FRANCE
 Bosch, Michael, Marsillargues, FRANCE
 Dos Santos, Victor, Valergues, FRANCE
 Herbert, Jean-Marc, Tournefeuille, FRANCE
 Nisato, Dino, Saint-Georges D'Orques, FRANCE
 Tonnerre, Bernard, Vailhauques, FRANCE
 Wagnon, Jean, Montpellier, FRANCE

PA sanofi-aventis, 75013 Paris, FRANCE (non-U.S. corporation)

PI US-20050176722 A1 20050811

AI 2003US-000516704 A1 20030605 (10)

2003WO-FR0001685 20030605

PRAI 2002FR-0000007001 20020607

DT Utility

FS APPLICATION

LREP SANOFI-AVENTIS, PATENT DEPARTMENT-MAIL CODE D-303A, ROUTE 202-206, P.O. BOX 6800, BRIDGEWATER, NJ, 08807, US

CLMN Number of Claims: 26

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2901

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to substituted 1-piperazinylacylpiperidine derivatives of general formula (I) ##STR1## in which: n is 1 or 2; p is 1 or 2;

R.sub.1 represents a halogen atom; a trifluoromethyl radical; a (C.sub.1-C.sub.4)alkyl; a (C.sub.1-C.sub.4)alkoxy; a trifluoromethoxy radical;

R.sub.2 represents a hydrogen atom or a halogen atom;

R.sub.3 represents a hydrogen atom; a group --OR.sub.5; a group --CH.sub.2OR.sub.5; a group --NR.sub.6R.sub.7; a group --NR.sub.8COR.sub.9; a group --NR.sub.8CONR.sub.10R.sub.11; a group --CH.sub.2NR.sub.12R.sub.13; a group --CH.sub.2NR.sub.8CONR.sub.14R.sub.15; a (C.sub.1-C.sub.4)alkoxycarbonyl; a group --CONR.sub.16R.sub.17;

or else R.sub.3 constitutes a double bond between the carbon atom to which it is attached and the adjacent carbon atom of the piperidine ring;

R.sub.4 represents an aromatic group selected from: ##STR2##

the said aromatic groups being unsubstituted or being mono- or disubstituted by a substituent selected independently from a halogen atom; a (C.sub.1-C.sub.4)alkyl; a (C.sub.1-C.sub.4)alkoxy; a trifluoromethyl radical; Preparation process and therapeutic application.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 634461-23-7P, 1-[4-(Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone


634461-69-1P 634462-72-9P 634462-91-2P

634463-08-4P 634463-19-7P 634463-39-1P

634464-66-7P 634525-03-4P

(NGF binding inhibitor; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the

- apoptosis induced by NGF)
- IT 634461-08-8P, 2-[4-(2-Pyrazinyl)-1-piperazinyl]-1-[4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-1-ethanone monohydrochloride
 634461-18-0P, 1-[4-Hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-3-[4-(2-(pyrazinyl))-1-piperazinyl]-1-propanone oxalate
 634462-26-3P 634462-32-1P 634462-38-7P
 634462-55-8P 634462-61-6P 634462-68-3P
 634462-79-6P, 1-[4-(Hydroxymethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
 634462-83-2P, 1-[4-[(Dimethylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634462-87-6P 634462-98-9P,
 1-[4-(4-Chlorophenyl)-3,6-dihydro-1(2H)-pyridinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634463-03-9P, 1-[4-(Aminomethyl)-4-(4-chlorophenyl)-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
 Trifluoroacetate 634463-13-1P 634463-23-3P
 634463-44-8P 634463-77-7P 634463-93-7P
 634464-08-7P, 1-[4-[(Methylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634464-15-6P, 1-[4-[(Isopropylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634464-20-3P, 1-[4-[(N-Methylisopropylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Trihydrochloride 634464-24-7P
 634464-29-2P 634464-34-9P 634464-39-4P
 634464-44-1P 634464-48-5P,
 1-[4-(Aminomethyl)-4-(3-chlorophenyl)-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone 634464-72-5P, 1-[4-(Aminomethyl)-4-(3-methoxyphenyl)-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Dioxalate 634470-24-9P 634525-08-9P
 (NGF binding inhibitor; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
- IT 634464-71-4P 634469-50-4P, 1-[2-[4-(2-Pyrazinyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinecarbonitrile 634469-57-1P, tert-Butyl [[1-[2-[4-(2-pyrazinyl)-1-piperazinyl]-1-oxoethyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinyl]methyl]carbamate
 634469-68-4P 634469-69-5P 634469-74-2P,
 4-(4-Chlorophenyl)-1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinecarbonitrile 634469-86-6P, tert-Butylmethyl [[1-[2-[4-(2-pyrazinyl)-1-piperazinyl]1-oxoethyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinyl]methyl]carbamate
 634469-90-2P, 4-(3-Chlorophenyl)-1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinecarbonitrile 634469-97-9P,
 4-(3-Methoxyphenyl)-1-[2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinecarbonitrile
 (intermediate; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
- IT 634469-80-0P, 1-[4-(Aminomethyl)-4-phenyl-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
 (intermediate; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
- IT 634469-81-1P, 1-[4-(Aminomethyl)-4-phenyl-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Trifluoroacetate
 (preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
- IT 634461-23-7P, 1-[4-(Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
 (NGF binding inhibitor; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
- RN 634461-23-7 USPATFULL
- CN 4-Piperidinemetanamine, 1-[(4-pyrazinyl-1-piperazinyl)acetyl]-4-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



=> d bib abs hitstr 120 tot

L20 ANSWER 1 OF 2 USPATFULL on STN

AN 2006:196251 USPATFULL

TI Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof

IN Bono, Françoise, Toulouse, FRANCE

Bosch, Michael, Marsillargues, FRANCE

Dos Santos, Victor, Valergues, FRANCE

Herbert, Jean-Marc, Tournefeuille, FRANCE

Nisato, Dino, Saint-Georges D'Orques, FRANCE

Tonnerre, Bernard, Vailhauques, FRANCE

Wagnon, Jean, Montpellier, FRANCE

PA sanofi-aventis, 75013 Paris, FRANCE (non-U.S. corporation)

PI US-20060167007 A1 20060727

AI 2003US-000516808 A1 20030605 (10)

2003WO-FR0001686 20030605

20041203 PCT 371 date

PRAI 2002FR-0000007001 20020607

DT Utility

FS APPLICATION

LREP ROSS J. OEHLER, AVENTIS PHARMACEUTICALS INC., 1041 ROUTE 202-206, MAIL CODE: D303A, BRIDGEWATER, NJ, 08807, US

CLMN Number of Claims: 14

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2025

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to substituted 1-piperazinylacylpiperidine derivatives of general formula (I) ##STR1## in which: n is 1 or 2;

R.sub.1 represents a halogen atom; a trifluoromethyl radical; a (C.sub.1-C.sub.4) alkyl; a (C.sub.1-C.sub.4)alkoxy; a trifluoromethoxy radical;

R.sub.2 represents a hydrogen atom or a halogen atom;

R.sub.3 represents a hydrogen atom; a group --OR.sub.5; a group --CH.sub.2OR.sub.5; a group --NR.sub.6R.sub.7; a group --NR.sub.8COR.sub.9; a group --NR.sub.8CONR.sub.10R.sub.11; a group --CH.sub.2NR.sub.12R.sub.13; a group --CH.sub.2NR.sub.8CONR.sub.14R.sub.15; a (C.sub.1-C.sub.4)alkoxycarbonyl; a group --CONR.sub.16R.sub.17;

or else R.sub.3 constitutes a double bond between the carbon atom to which it is attached and the adjacent carbon atom of the piperidine ring;

R.sub.4 represents the aromatic group 1,3-thiazol-2-yl of formula: ##STR2## Preparation process and therapeutic application.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 634462-55-8P 634462-61-6P


(NGF binding inhibitor; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)

RN 634462-55-8 USPATFULL

CN Pyridine, 1,2,3,6-tetrahydro-1-[(4-pyrazinyl-1-piperazinyl)acetyl]-4-[3-(trifluoromethyl)phenyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 634462-54-7
CMF C22 H24 F3 N5 O



CM 2


CRN 144-62-7
CMF C2 H2 O4



RN 634462-61-6 USPATFULL
CN Pyridine, 1,2,3,6-tetrahydro-1-[(4-pyrazinyl-1-piperazinyl)acetyl]-4-[2-(trifluoromethyl)phenyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)


CM 1'

CRN 634462-60-5
CMF C22 H24 F3 N5 O



CM 2

CRN 144-62-7
CMF C2 H2 O4



L20 ANSWER 2 OF 2 USPATFULL on STN
AN 2005:203297 USPATFULL
TI Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
IN Bono, Françoise, Toulouse, FRANCE
Bosch, Michael, Marsillargues, FRANCE
Dos Santos, Victor, Valergues, FRANCE
Herbert, Jean-Marc, Tournefeuille, FRANCE
Nisato, Dino, Saint-Georges D'Orques, FRANCE
Tonnerre, Bernard, Vailhauques, FRANCE
Wagnon, Jean, Montpellier, FRANCE
PA sanofi-aventis, 75013 Paris, FRANCE (non-U.S. corporation)
PI US-20050176722 A1 20050811
AI 2003US-000516704 A1 20030605 (10)
2003WO-FR0001685 20030605
PRAI 2002FR-0000007001 20020607
DT Utility
FS APPLICATION
LREP SANOFI-AVENTIS, PATENT DEPARTMENT-MAIL CODE D-303A, ROUTE 202-206, P.O.

BOX 6800, BRIDGEWATER, NJ, 08807, US

CLMN Number of Claims: 26

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2901

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to substituted 1-piperazinylaclylpiperidine derivatives of general formula (I) ##STR1## in which: n is 1 or 2; p is 1 or 2;

R.sub.1 represents a halogen atom; a trifluoromethyl radical; a (C.sub.1-C.sub.4)alkyl; a (C.sub.1-C.sub.4)alkoxy; a trifluoromethoxy radical;

R.sub.2 represents a hydrogen atom or a halogen atom;

R.sub.3 represents a hydrogen atom; a group --OR.sub.5; a group --CH.sub.2OR.sub.5; a group --NR.sub.6R.sub.7; a group --NR.sub.8COR.sub.9; a group --NR.sub.8CONR.sub.10R.sub.11; a group --CH.sub.2NR.sub.12R.sub.13; a group --CH.sub.2NR.sub.8CONR.sub.14R.sub.15; a (C.sub.1-C.sub.4)alkoxycarbonyl; a group --CONR.sub.16R.sub.17; or else R.sub.3 constitutes a double bond between the carbon atom to which it is attached and the adjacent carbon atom of the piperidine ring;

R.sub.4 represents an aromatic group selected from: ##STR2## the said aromatic groups being unsubstituted or being mono- or disubstituted by a substituent selected independently from a halogen atom; a (C.sub.1-C.sub.4)alkyl; a (C.sub.1-C.sub.4)alkoxy; a trifluoromethyl radical; Preparation process and therapeutic application.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 634462-55-8P 634462-61-6P

(NGF binding inhibitor; preparation of piperazinylaclylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)


RN 634462-55-8 USPTFULL

CN Pyridine, 1,2,3,6-tetrahydro-1-[(4-pyrazinyl-1-piperazinyl)acetyl]-4-[3-(trifluoromethyl)phenyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 634462-54-7


CMF C22 H24 F3 N5 O



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 634462-61-6 USPTFULL

CN Pyridine, 1,2,3,6-tetrahydro-1-[(4-pyrazinyl-1-piperazinyl)acetyl]-4-[2-(trifluoromethyl)phenyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 634462-60-5

CMF C22 H24 F3 N5 O



CM 2

CRN 144-62-7
CMF C2 H2 O4

=> d his

(FILE 'HOME' ENTERED AT 14:33:14 ON 27 JUL 2007)

FILE 'HCAPLUS' ENTERED AT 14:33:22 ON 27 JUL 2007

L1 2 US20050176722/PN OR (US2004-516704 OR FR2002-07001 OR WO2003-FR

FILE 'REGISTRY' ENTERED AT 14:40:52 ON 27 JUL 2007

FILE 'HCAPLUS' ENTERED AT 14:40:56 ON 27 JUL 2007

L2 TRA L1 1- RN : 244 TERMS

FILE 'REGISTRY' ENTERED AT 14:40:57 ON 27 JUL 2007

L3 244 SEA L2

L4 104 L3 AND NC5/ES AND (NC2NC2 OR NC2NC3)/ES

L5 STR

E PYRAZINE/CN

L6 1 E3

L7 STR L5

L8 7 L7

L9 127 L7 FULL

L10 73363 46.383.21/RID

L11 98 L9 AND L10

L12 71 L9 AND L3

L13 50 L11 AND L12

FILE 'HCAPLUS' ENTERED AT 15:23:51 ON 27 JUL 2007

L14 2 L11

FILE 'REGISTRY' ENTERED AT 15:27:58 ON 27 JUL 2007

SAV TEM L9 J704/A

L15 6 C22H24F3N5O AND L9

L16 4 L15 AND L10

FILE 'HCAPLUS' ENTERED AT 15:30:36 ON 27 JUL 2007

L17 1 L16

FILE 'HCAOLD' ENTERED AT 15:31:32 ON 27 JUL 2007

L18 0 L11 OR L16

FILE 'USPATFULL, USPAT2' ENTERED AT 15:32:14 ON 27 JUL 2007

L19 3 L11

FILE 'USPATFULL, USPAT2' ENTERED AT 15:32:43 ON 27 JUL 2007

L20 2 L16

=>